propranolol

conditioned fear freezing (%) at drug-free retention Test 1

no effect, n = 215

A Bayesian meta-analysis including all 9 experiments indicated weak evidence in favor of the absence of a group difference at Test.

PMID:38733644 · one of two readings recorded this

conditioned fear freezing behaviour (% time) during extinction training and drug-free retention testing in rats, and fear-potentiated startle, skin conductance response and US expectancy in a human fear-conditioning study, following propranolol versus saline/placebo prior to extinction

decreases, n = 215

Not recorded as a finding: this platform holds no node for the endpoint

A Bayesian meta-analysis including all 9 experiments indicated extreme evidence for a group difference, with PROP rats showing less freezing than SAL rats during Extinction.

PMID:38733644 · one of two readings recorded this

conditioned fear freezing (%) during extinction training

decreases, n = 215

A Bayesian meta-analysis including all 9 experiments indicated extreme evidence for a group difference, with PROP rats showing less freezing than SAL rats during Extinction.

PMID:38733644 · one of two readings recorded this

extinction learning (US expectancy, fear-potentiated startle, skin conductance) on Day 2

no effect, n = 72

The absence of significant Group effects and of interactions with Group, however, indicate that there were no significant differences in extinction learning between the 3 groups.

PMID:38733644 · one of two readings recorded this

fear-potentiated startle, skin conductance response, and US expectancy during extinction learning

no effect, n = 72

The absence of significant Group effects and of interactions with Group, however, indicate that there were no significant differences in extinction learning between the 3 groups.

PMID:38733644 · one of two readings recorded this

freezing at drug-free retention Test 1 (percentage time freezing to conditioned tone)

no effect, n = 215

In most experiments, there was no evidence for a group difference.

PMID:38733644 · one of two readings recorded this

freezing during the 12 Extinction trials (percentage time freezing to conditioned tone)

decreases, n = 215

Freezing during the 12 Extinction trials was significantly lower in PROP than SAL rats in Experiments 1, 2, 4, 6 and 8.

PMID:38733644 · one of two readings recorded this

freezing to conditioned tones during extinction training and drug-free retention testing (fear extinction memory retention), plus salivary alpha-amylase, heart rate, blood pressure and subjective arousal as manipulation checks

no effect

Not recorded as a finding: this platform holds no node for the endpoint

In most experiments, there was no evidence for a group difference.

PMID:38733644 · one of two readings recorded this

salivary alpha-amylase, heart rate, systolic and diastolic blood pressure

decreases, n = 72

As expected, propranolol acutely lowered salivary α-amylase (marker of noradrenergic activity), heart rate, systolic and diastolic blood pressure.

PMID:38733644 · one of two readings recorded this

salivary alpha-amylase, heart rate, systolic and diastolic blood pressure (acute manipulation check)

decreases, n = 72

As expected, propranolol acutely lowered salivary α-amylase (marker of noradrenergic activity), heart rate, systolic and diastolic blood pressure.

PMID:38733644 · one of two readings recorded this

subjective arousal rating

no effect, n = 72

In contrast with the clearly significant effects on α-amylase, heart rate and blood pressure, there was no significant effect of propranolol on subjective arousal.

PMID:38733644 · one of two readings recorded this

subjective arousal ratings (9-point scale)

no effect, n = 72

In contrast with the clearly significant effects on α-amylase, heart rate and blood pressure, there was no significant effect of propranolol on subjective arousal.

PMID:38733644 · one of two readings recorded this

reduction in monthly migraine days

decreases, -1.27; 95% CI: -2.25 to -0.3, n = 1291

The analysis revealed a moderate certainty evidence that propranolol leads to a reduction in monthly migraine days versus placebo (-1.27; 95% CI: -2.25 to -0.3).

PMID:39044170 · both readings recorded this

reduction in monthly migraine days, RCT meta-analysis of propranolol versus placebo

decreases, -1.27; 95% CI: -2.25 to -0.3, n = 1291

Not recorded as a finding: no outcome node exists for migraine-day frequency/mean reduction; node list has no migraine-frequency endpoint

The analysis revealed a moderate certainty evidence that propranolol leads to a reduction in monthly migraine days versus placebo (-1.27; 95% CI: -2.25 to -0.3).

PMID:39044170 · one of two readings recorded this

calcification, bone glutamate protein, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, cortisol, and adrenocorticotropic hormone

n = 1543

In addition, calcification, bone glutamate protein, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, cortisol, and adrenocorticotropic hormone were significantly different between the 2 groups (P < .05).

PMID:39533554 · one of two readings recorded this

calcification, bone glutamate protein, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, cortisol, and adrenocorticotropic hormone levels

n = 1543

In addition, calcification, bone glutamate protein, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, cortisol, and adrenocorticotropic hormone were significantly different between the 2 groups (P < .05).

PMID:39533554 · one of two readings recorded this

cure rate, total effective rate, and heart rate

increases, n = 1543

The results of the meta-analysis demonstrated that methimazole combined with propranolol improved the cure rate, the total effective rate, and heart rate, compared with the control group (P < .05).

PMID:39533554 · both readings recorded this

cure rate, total effective rate, and heart rate; also calcification, bone glutamate protein, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, cortisol, and adrenocorticotropic hormone levels, in methimazole-treated hyperthyroidism patients with propranolol added versus methimazole alone

increases

Not recorded as a finding: no estimate is reported anywhere

The results of the meta-analysis demonstrated that methimazole combined with propranolol improved the cure rate, the total effective rate, and heart rate, compared with the control group (P < .05).

PMID:39533554 · one of two readings recorded this

cure rate, total effective rate, and heart rate in patients with hyperthyroidism, methimazole combined with propranolol versus methimazole alone

increases, n = 1543

Not recorded as a finding: no estimate is reported anywhere

The results of the meta-analysis demonstrated that methimazole combined with propranolol improved the cure rate, the total effective rate, and heart rate, compared with the control group (P < .05).

PMID:39533554 · one of two readings recorded this

leukemia, headache, dizziness, skin pruritus, bone pain, arthralgia, parathyroid hormone improvement, gastrointestinal reactions

no effect, n = 1543

There were no significant differences in leukemia, headache, dizziness, skin pruritus, bone pain, arthralgia, or in improving parathyroid hormone or reducing gastrointestinal reactions between the 2 groups.

PMID:39533554 · one of two readings recorded this

leukopenia, headache, dizziness, skin pruritus, bone pain, arthralgia, parathyroid hormone, gastrointestinal reactions

no effect, n = 1543

There were no significant differences in leukemia, headache, dizziness, skin pruritus, bone pain, arthralgia, or in improving parathyroid hormone or reducing gastrointestinal reactions between the 2 groups.

PMID:39533554 · one of two readings recorded this

cardiac output decrease

decreases, MD = 0.92, 95% CI = 0.45-1.38; p = 0.004, p = 0.004, n = 351

Decrease in cardiac output was greater in the propranolol group (MD = 0.92, 95% CI = 0.45-1.38; p = 0.004).

PMID:40387434 · one of two readings recorded this

cardiac output reduction

MD = 0.92, 95% CI = 0.45-1.38, p = 0.004, n = 351

Decrease in cardiac output was greater in the propranolol group (MD = 0.92, 95% CI = 0.45-1.38; p = 0.004).

PMID:40387434 · one of two readings recorded this

hepatic venous pressure gradient (HVPG) reduction

decreases, MD = -0.76, 95% CI = -1.45 to -0.08; p = 0.03, p = 0.03, n = 351

Reduction in hepatic venous pressure gradient was significantly greater in the carvedilol group (MD = -0.76, 95% CI = -1.45 to -0.08; p = 0.03).

PMID:40387434 · one of two readings recorded this

hepatic venous pressure gradient reduction

MD = -0.76, 95% CI = -1.45 to -0.08, p = 0.03, n = 351

Reduction in hepatic venous pressure gradient was significantly greater in the carvedilol group (MD = -0.76, 95% CI = -1.45 to -0.08; p = 0.03).

PMID:40387434 · one of two readings recorded this

mean pulmonary arterial pressure decrease

no effect, MD = -0.75, 95% CI = -1.60 to 0.10; p = 0.08, p = 0.08, n = 351

Decrease in mean pulmonary arterial pressure appeared to be greater in the carvedilol group; however, this was not statistically significant (MD = -0.75, 95% CI = -1.60 to 0.10; p = 0.08).

PMID:40387434 · one of two readings recorded this

rebleeding, shortness of breath, hepatic encephalopathy, hypotension incidence

no effect, n = 351

There was no difference in incidence of rebleeding, shortness of breath, hepatic encephalopathy, and hypotension between the two groups.

PMID:40387434 · one of two readings recorded this

adverse event incidence

no effect, OR = 0.95, 95% CI: 0.54-1.70, p = 0.87, n = 719

The pooled analysis indicated no significant difference in adverse event incidence between the propranolol and control groups (OR = 0.95, 95% CI: 0.54–1.70, p = 0.87) (Table 5).

PMID:41700540 · one of two readings recorded this

overall treatment response rate (≥50% reduction in lesion size)

no effect, OR = 1.29, 95% CI: 0.80-2.09, p = 0.2977, n = 900

The pooled analysis showed no statistically significant difference between propranolol and control groups (OR = 1.29, 95% CI: 0.80–2.09, p = 0.2977) (Table 4).

PMID:41700540 · one of two readings recorded this

adverse event incidence

increases, OR = 0.14, 95% CrI: 0.03–0.57 (placebo relative to propranolol), n = 1143

Compared with oral propranolol, corticosteroids were associated with higher odds of adverse events (OR = 52.92, 95% CrI: 3.12–2,874.40), whereas placebo showed significantly lower odds (OR = 0.14, 95% CrI: 0.03–0.57).

PMID:42479211 · one of two readings recorded this

adverse event incidence, propranolol vs corticosteroids

decreases

Compared with oral propranolol, corticosteroids were associated with higher odds of adverse events (OR = 52.92, 95% CrI: 3.12–2,874.40), whereas placebo showed significantly lower odds (OR = 0.14, 95% CrI: 0.03–0.57).

PMID:42479211 · one of two readings recorded this

adverse event incidence, propranolol vs placebo

increases, OR = 0.14, 95% CrI: 0.03-0.57 (placebo vs propranolol reference)

Compared with oral propranolol, corticosteroids were associated with higher odds of adverse events (OR = 52.92, 95% CrI: 3.12–2,874.40), whereas placebo showed significantly lower odds (OR = 0.14, 95% CrI: 0.03–0.57).

PMID:42479211 · one of two readings recorded this

treatment success rate (complete lesion resolution or >75% reduction in lesion size at 6 months) for infantile hemangioma, oral propranolol as network reference versus placebo/observation and seven other active interventions

increases, OR = 0.12, 95% CrI: 0.03-0.52 (placebo/observation vs oral propranolol reference)

Not recorded as a finding: this platform holds no node for the endpoint

Using oral propranolol as the reference, only placebo/observation showed a statistically significant difference (OR = 0.12, 95% CrI: 0.03–0.52), demonstrating propranolol’s superiority over no active treatment.

PMID:42479211 · one of two readings recorded this

treatment success rate (complete lesion resolution or >75% reduction in size at 6 months)

increases, OR = 0.12, 95% CrI: 0.03–0.52, n = 2639

Using oral propranolol as the reference, only placebo/observation showed a statistically significant difference (OR = 0.12, 95% CrI: 0.03–0.52), demonstrating propranolol’s superiority over no active treatment.

PMID:42479211 · one of two readings recorded this

treatment success rate (complete lesion resolution or >75% reduction in size at 6 months) and adverse event incidence, Bayesian network meta-analysis anchored on oral propranolol

increases, OR = 0.12, 95% CrI: 0.03–0.52, n = 2639

Not recorded as a finding: this platform holds no node for the endpoint

Using oral propranolol as the reference, only placebo/observation showed a statistically significant difference (OR = 0.12, 95% CrI: 0.03–0.52), demonstrating propranolol’s superiority over no active treatment.

PMID:42479211 · one of two readings recorded this

treatment success rate (complete resolution or >75% size reduction at 6 months)

increases, OR = 0.12, 95% CrI: 0.03-0.52 (placebo vs propranolol reference)

Using oral propranolol as the reference, only placebo/observation showed a statistically significant difference (OR = 0.12, 95% CrI: 0.03–0.52), demonstrating propranolol’s superiority over no active treatment.

PMID:42479211 · one of two readings recorded this